Navigation Links
Chesley Files Federal Zicam Lawsuits
Date:3/4/2010

CINCINNATI, March 4 /PRNewswire/ -- Stanley M. Chesley from the Cincinnati, Ohio-based law firm of Waite, Schneider, Bayless & Chesley Co., L.P.A. yesterday filed federal lawsuits in Ohio and Kentucky against Matrixx Initiatives, the manufacturer of Zicam, on behalf of four local residents who lost their senses of taste and smell after using the popular over-the-counter cold and flu nasal gel.

The lawsuits allege that Matrixx knew for years that Zicam users had complained of anosmia, or loss of smell, but explicitly chose not to warn Zicam customers.  

On June 16, 2009 the Food and Drug Administration issued a warning advising consumers to "stop using and discard" Zicam Cold Remedy Nasal Gel and Cold Remedy Nasal Swabs (among others) because Zicam is "associated with the loss of sense of smell."   In light of the FDA's warning, the lawsuit alleges, Matrixx had no choice but to immediately recall the dangerously defective Zicam products.

"The problem here is that Matrixx repeatedly refused to protect consumers of its products until the FDA forced its hand," noted Chesley.  "With these lawsuits, our clients intend to send a message that the American public will not stand by while another drug manufacturer secretly attempts to put its profits ahead of public safety."

The cases, Raker et al v. Matrixx Initiatives, Inc. et al., (Case Number 10-cv-000125, S.D. Ohio) and Hartman v. Matrixx Initiatives, Inc. et al., (Case Number 10-cv-00042, E.D. Ky.), allege negligence, defect in design and manufacture, failure to warn, breach of warranties, fraudulent concealment, and state consumer laws

CONTACT: Stanley M. Chesley, Robert A. Steinberg, or Renee A. Infante at (513) 621-0267

SOURCE Waite, Schneider, Bayless & Chesley Co., L.P.A.

Back to top
'/>"/>
SOURCE Waite, Schneider, Bayless & Chesley Co., L.P.A.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. AngioGenex Files Patent on First Small Molecule Id-Inhibitors for the Treatment of Cancer
4. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Further Clinical Testing of BZL101 in Advanced Breast Cancer Demonstrates Favorable Efficacy and Toxicity Profiles
7. Vermillion Files 510(k) Application With U.S. Food & Drug Administration for OVA1 Ovarian Tumor Triage Test
8. FDA Files Application To Convert ONTAK(R) (Denileukin Diftitox) to Full Approval for Use in Cutaneous T-Cell Lymphoma (CTCL)
9. Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer
10. ASX/NASDAQ Media Release: Pharmaxis Files First Marketing Application for Bronchitol in Australia
11. deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimers and Other Cognitive Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... 28, 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), ... call and webcast on Friday, November 3, 2017, beginning ... ending at approximately 8:30 a.m. (CDT) / 9:30 a.m. ... 2017 financial performance and guidance for 2018, Hill-Rom executives ... enhance operational performance, and long-range financial outlook through 2020. ...
(Date:9/27/2017)... NEW YORK , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), ... solutions, today announced that its MyDario product is expected to appear on ... for when The Dr. Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. ... ...
(Date:9/23/2017)... Pa. , Sept. 22, 2017 Janssen ... a complete response letter from the U.S. Food and ... seeking approval of sirukumab for the treatment of moderately ... letter indicates additional clinical data are needed to further ... moderately to severely active RA. ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... agency serving communities in the greater Dallas, Miami, and Raleigh regions, is organizing ... fighting to overcome a rare and deadly chromosome abnormality. , After struggling since ...
(Date:10/13/2017)... IL (PRWEB) , ... October 13, 2017 , ... ... which established the certification process to promote standards of excellence for the field ... Symposium, scheduled for March 22 – 25, 2018 in Orlando, Florida at the ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers ... companies have a waiver for care if the client has a cognitive impairment diagnosis. ... pays for care, is often waived, so the benefits from their insurance start immediately,” ...
(Date:10/13/2017)... ... , ... Talented host, actor Rob Lowe, is introducing a ... episode of "Success Files," which is an award-winning educational program broadcasted on PBS ... in-depth with passion and integrity. , Sciatica occurs when the sciatic nerve in ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
Breaking Medicine News(10 mins):